These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 15671616)
1. Risk of alveolar hemorrhage in patients with primary pulmonary hypertension--anticoagulation and epoprostenol therapy. Ogawa A; Matsubara H; Fujio H; Miyaji K; Nakamura K; Morita H; Saito H; Kusano KF; Emori T; Date H; Ohe T Circ J; 2005 Feb; 69(2):216-20. PubMed ID: 15671616 [TBL] [Abstract][Full Text] [Related]
2. [Acute circulatory failure caused by primary pulmonary hypertension or pulmonary embolism]. Meyer G; Sanchez O Rev Mal Respir; 2000 Feb; 17(1):51-65. PubMed ID: 10756556 [TBL] [Abstract][Full Text] [Related]
3. Anti-coagulation complications in pregnancies with severe pulmonary arterial hypertension. Herrero T; Martin E; Poch DS; Roeder HA J Matern Fetal Neonatal Med; 2018 May; 31(9):1209-1213. PubMed ID: 28353362 [TBL] [Abstract][Full Text] [Related]
4. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477 [TBL] [Abstract][Full Text] [Related]
5. Paradoxical effect of prostacyclin infusion in a patient with primary pulmonary hypertension-a case report. Younger JR; Lui CY Angiology; 2004; 55(3):341-4. PubMed ID: 15156270 [TBL] [Abstract][Full Text] [Related]
6. [Education of patients treated with a continuous epoprostenol infusion for pulmonary hypertension]. Marlier D Soins; 2006 May; (705 Suppl):S7-12. PubMed ID: 16771257 [No Abstract] [Full Text] [Related]
13. Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil. Ascha M; Zhou X; Rao Y; Minai OA; Tonelli AR Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28643420 [TBL] [Abstract][Full Text] [Related]
14. Role of prostacyclin (epoprostenol) as anticoagulant in continuous renal replacement therapies: efficacy, security and cost analysis. Gainza FJ; Quintanilla N; Pijoan JI; Delgado S; Urbizu JM; Lampreabe I J Nephrol; 2006; 19(5):648-55. PubMed ID: 17136695 [TBL] [Abstract][Full Text] [Related]
15. [Clinico-hemodynamic study and treatment of 44 patients with primary pulmonary hypertension]. Roman A; Rodés-Cabau J; Lara B; Bravo C; Monforte V; Pallissa E; Domingo E; Morell F Med Clin (Barc); 2002 Jun; 118(20):761-6. PubMed ID: 12049690 [TBL] [Abstract][Full Text] [Related]
16. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. Sitbon O; Humbert M; Nunes H; Parent F; Garcia G; Hervé P; Rainisio M; Simonneau G J Am Coll Cardiol; 2002 Aug; 40(4):780-8. PubMed ID: 12204511 [TBL] [Abstract][Full Text] [Related]
17. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma. Farber HW; Graven KK; Kokolski G; Korn JH J Rheumatol; 1999 May; 26(5):1195-6. PubMed ID: 10332990 [TBL] [Abstract][Full Text] [Related]
18. A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension. Robbins IM; Christman BW; Newman JH; Matlock R; Loyd JE Chest; 1998 Nov; 114(5):1269-75. PubMed ID: 9824000 [TBL] [Abstract][Full Text] [Related]